Study and analysis of the use of bevacizumab in the treatment of breast cancer

Tong Xu

doi:10.62051/xxztj722

Authors

Tong Xu

DOI:

https://doi.org/10.62051/xxztj722

Keywords:

Bevacizumab, Breast cancer, Reversed-phase protein array technology, Protein expression.

Abstract

This study aimed to explore the application of bevacizumab in breast cancer treatment. We reviewed the research progress and current status of bevacizumab, analyzed its mechanism of action, and introduced protein expression analysis to further investigate its therapeutic effect. Bevacizumab is an angiogenesis inhibitor that prevents tumor growth by binding to and blockingvascular endothelial growth factor (VEGF). Data were obtained derived from the United States Society of Clinical Oncology (ASCO), which employed reversed-phase protein array technology (RPPA) to analyze the expression levels of related proteins. This included data on 210 proteins from 55 CTx samples and 54 Bev + CTx samples. We conducted a follow-up analysis based on the existing studies of nine protein signatures with corresponding beta coefficients identified by Lasso regression. However, only the first eight proteins were analyzed due to insufficient data. Additionally, we analyzed four of the 210 proteins with high expression levels. Statistical analysis revealed differences in protein the expression levels between the CTx and Bev + CTx groups, though these differences were not statistically significant. Clustering results displayed protein expression data through heat maps, revealing a clustering relationship among several proteins. This study provides a reference for the application of bevacizumab in breast cancer treatment.

Downloads

Download data is not yet available.

References

[1] Key T J, Verkasalo P K, Banks E. Epidemiology of breast cancer[J]. The lancet oncology, 2001, 2(3): 133-140.

[2] Connolly Jr J E, Erasmus J J, Patz Jr E F. Thoracic manifestations of breast carcinoma: metastatic disease and complications of treatment[J]. Clinical radiology, 1999, 54(8): 487-494.

[3] Shimizu K, Oku N. Cancer anti-angiogenic therapy[J]. Biological and Pharmaceutical Bulletin, 2004, 27(5): 599-605.

[4] Kubota Y. Tumor angiogenesis and anti-angiogenic therapy[J]. The Keio journal of medicine, 2012, 61(2): 47-56.

[5] Teleanu R I, Chircov C, Grumezescu A M, et al. Tumor angiogenesis and anti-angiogenic strategies for cancer treatment[J]. Journal of clinical medicine, 2019, 9(1): 84.

[6] Midgley R, Kerr D. Bevacizumab—current status and future directions[J]. Annals of Oncology. 2005 Jul;16(7):999-1004.

[7] Jenab-Wolcott J, Giantonio BJ. Bevacizumab: current indications and future development for management of solid tumors[J]. Expert Opinion on Biological Therapy. 2009 Apr;9(4):507-517.

[8] Garcia J, et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook[J]. Cancer Treatment Reviews. 2020;86:102017.

[9] Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature[J]. Expert Review of Anticancer Therapy. 2012 May;12(5):567-580.

[10] Charboneau L, et al. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays[J]. Briefings in Functional Genomics. 2002;1(3):305-315.

[11] Haugen MH, et al. Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers[J]. JCO Precis Oncol. 2021;5:286-306.

[12] Spisak S, Guttman A. Biomedical applications of protein microarrays[J]. Current Medicinal Chemistry. 2009;16(22):2806-2815.